The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Antibody-Based Immunotherapy of Cancer
Open accessAbstract
By targeting surface antigens expressed on tumor cells, monoclonal antibodies have demonstrated efficacy as cancer therapeutics. Recent successful antibody-based strategies have focused on enhancing anti-tumor immune responses by targeting immune cells, irrespective of tumor antigens. We discuss these innovative strategies and propose how they will impact the future of antibody-based cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 2×
“Activating FcRs involved in immune effector activities are important for anti-tumor effects (Clynes et al., 2000).”
BackgroundSauter, B., Albert, M. L., Francisco, L., Larsson, M., Somersan, S., & Bhardwaj, N. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.3.423 · Cited by 1,358
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Self-citationThe role of TNF superfamily members in T-cell function and diseases
Croft, M. (2009) · Nature Reviews Immunology · doi:10.1038/nri2526 · Cited by 920
Dhodapkar, K. M., Krasovsky, J., Williamson, B., & Dhodapkar, M. V. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011097 · Cited by 349
Schaefer, G., Haber, L., Crocker, L. M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C. V., Stawicki, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341
Li, F., & Ravetch, J. V. (2011) · Science · doi:10.1126/science.1206954 · Cited by 335
Advances in the assessment and control of the effector functions of therapeutic antibodies
Jiang, X.-R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., Chung, S., Strouse, R., Mire-Sluis, A., & Schenerman, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3365 · Cited by 299
Wilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S., Lawrence, D., Li, Y., Pitti, R., Totpal, K., Yee, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.012 · Cited by 248
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
Ruf, P., & Lindhofer, H. (2001) · Blood · doi:10.1182/blood.v98.8.2526 · Cited by 174
Lutterbuese, R., Raum, T., Kischel, R., Hoffmann, P., Mangold, S., Rattel, B., Friedrich, M., Thomas, O., Lorenczewski, G., Rau, D., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000976107 · Cited by 166
Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
Steiner, M., & Neri, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0483 · Cited by 157
Hilchey, S. P., Hyrien, O., Mosmann, T. R., Livingstone, A. M., Friedberg, J. W., Young, F. M., Fisher, R. I., Kelleher, R. J., Bankert, R. B., & Bernstein, S. H. (2009) · Blood · doi:10.1182/blood-2008-10-185280 · Cited by 156
Chemical generation of bispecific antibodies
Doppalapudi, V. R., Huang, J., Liu, D., Jin, P., Liu, B., Li, L., Desharnais, J., van Hagen, C., Levin, N. J., Shields, M. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016478108 · Cited by 124
Targeting Intracellular Oncoproteins with Antibody Therapy or Vaccination
Guo, K., Li, J., Tang, J. P., Tan, C. P. B., Hong, C. W., Al-Aidaroos, A. Q., Varghese, L., Huang, C., & Zeng, Q. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002296 · Cited by 99
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Cancer nanomedicines: So many papers and so few drugs!
Venditto, V. J., & Szoka, F. C. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.038 · Cited by 537
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 323
Inorganic nanoparticles for biomedicine: where materials scientists meet medical research
Giner-Casares, J. J., Henriksen-Lacey, M., Coronado-Puchau, M., & Liz-Marzán, L. M. (2016) · Materials Today · doi:10.1016/j.mattod.2015.07.004 · Cited by 317
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy
Gül, N., Babes, L., Siegmund, K., Korthouwer, R., Bögels, M., Braster, R., Vidarsson, G., ten Hagen, T. L. M., Kubes, P., & van Egmond, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66776 · Cited by 275
Metadata
- Authors
- Weiner, L. M., Murray, J. C., & Shuptrine, C. W.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 148
- Issue
- 6
- Pages
- 1081-1084
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W1966122087
- Cited by
- 284
- References
- 19
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.